Slide 1

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology


Slide 2

 


Slide 3

Designed to be the Most Potent Payload in Targeted Oncology


Slide 4

Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2027


Slide 5

Deep Leadership Across Radiopharmaceutical and Drug Development


Slide 6

The Perspective Story in Four Parts


Slide 7

Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve


Slide 8

Targeted Delivery of Payloads is Transforming Oncology Therapy


Slide 9

$45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue


Slide 10

Four Programs Address a Combined $45B+ Solid Tumor Market


Slide 11

Pipeline in Depth: The Data Behind Each Program


Slide 12

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals


Slide 13

Neuroendocrine Tumors Bamzireotide Navoxetan (VMT-α-NET)


Slide 14

 


Slide 15

Ongoing Phase 1/2a to Establish Broad Therapeutic Window


Slide 16

 


Slide 17

 


Slide 18

 


Slide 19

Durable Ongoing Disease Control


Slide 20

 


Slide 21

 


Slide 22

 


Slide 23

 


Slide 24

 


Slide 25

Bamzireotide Navoxetan’s Compelling Profile Supports Pre-Phase 3 Activities


Slide 26

Melanoma Lapemelanotide zapixetar


Slide 27

Checkpoint Inhibitors Transformed Melanoma Care but Still Leave Many Behind


Slide 28

Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma


Slide 29

Ongoing Phase 1/2a Open-Label Trial For Lapemelanotide Zapixetar in Melanoma


Slide 30

Preliminary Anti-tumor Activity Observed at 3.0 x 3 mCi Dose


Slide 31

Generally Well-Tolerated


Slide 32

Lapemelanotide Zapixetar Clinical Data Support Further Development


Slide 33

PSV359 Advanced Solid Tumors


Slide 34

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors


Slide 35

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential


Slide 36

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors


Slide 37

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent


Slide 38

CCK2R81 a potential first-in-class in selected solid tumors


Slide 39

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa


Slide 40

Platform and Manufacturing


Slide 41

Optimizing Structural Chemistry:


Slide 42

Choosing the Right Isotope


Slide 43

Not All ²¹²Pb Programs Are Created Equal


Slide 44

Advancing a Theranostic Approach:


Slide 45

Direct-to-Hospital Delivery through Integrated Isotope Production


Slide 46

Reaching the Largest Addressable Market with Regional Manufacturing


Slide 47

Financial Strength and IP


Slide 48

 


Slide 49

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain


Slide 50

A Decade of Deliberate, End-to-End Engineering


Slide 51

Built Over a Decade - The Platform Is Built; Pipeline Advancing


Slide 52

 


Slide 53

Abbreviations


Slide 54

APPENDIX – Backup Slides


Slide 55

Investment thesis


Slide 56

Engineering the Alpha Advantage in Targeted Oncology


Slide 57

Optimizing the Entire System for Targeted Oncology


Slide 58

Advancing a Diverse 212Pb-Based Oncology Portfolio


Slide 59

Market opportunity


Slide 60

Solid Tumors are an Attractive Market for Radiopharmaceuticals


Slide 61

 


Slide 62

2L+ Metastatic Melanoma Trials


Slide 63

Bamzireotide navoxetan (VMT-α-NET)


Slide 64

Designed with Broad Therapeutic Window


Slide 65

Dosimetry: Independent Investigator Findings


Slide 66

Dosimetry: Highlights from the Phase 1 Study


Slide 67

Baseline Patient Characteristics in NANETS 2026 Data Analysis


Slide 68

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment


Slide 69

Lapemelanotide zapixetar (VMT01)


Slide 70

ICI Combo Rationale: Strong Synergy with Lapemelanotide Zapixetar in Melanoma


Slide 71

Metastatic Melanoma: Post Second line plus


Slide 72

PSV359


Slide 73

 


Slide 74

 


Slide 75

PSV359 is Active Against FAP-α Expression on Tumor and on Stroma


Slide 76

Platform and Manufacturing


Slide 77

 


Slide 78

Designed for Better Clinical Outcome


Slide 79

212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors


Slide 80

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure


Slide 81

 


Slide 82

 


Slide 83

On-Demand Fulfillment at Regional Sites for Finished Product Delivery


Slide 84

Ideal for Regional Manufacturing


Slide 85

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product


Slide 86

IP protection


Slide 87